Proton Therapy for Mediastinal Lymphoma (PROMLY)

The study aims to investigate whether proton therapy is feasible in a national setting and whether proton therapy can reduce the risk of late toxicity (secondary cancers and heart toxicity) compared to foton therapy.

Trial Details

NCT ID
NCT07817641
Phase
NA
Sponsor
Copenhagen University Hospital, Rigshospitalet
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • Proton therapy
Locations (sample)
  • Copenhagen, Select A State, Denmark|55.67594,12.56553

Key Eligibility Criteria

  • Patients 18 years or older
  • Histologically proven Hodgkin or non-Hodgkin lymphoma
  • Disease constrained within the mediastinum +/- neck and/or axilla involvement.
  • Candidates for curative intended treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →